Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.
TL;DR
- Novo Nordisk's stock saw its worst year on record due to guidance cuts, rival advancements, leadership changes, and copycat drugs.
- The U.S. approval of oral Wegovy, the first GLP-1 pill for weight loss, boosted Novo's shares and provides a competitive edge.
- Wegovy pill shows comparable efficacy to its injectable form with added patient convenience, a key advantage over injectables.
- Eli Lilly's orforglipron is expected soon, intensifying competition in the oral weight loss drug market.
- Novo's strategy emphasizes treating obesity as a disease and addressing related co-morbidities, though market focus appears to be on maximum weight loss.
- Direct-to-consumer marketing and pricing negotiations, including a deal with the Trump administration, are critical for future growth.
- Novo faces headwinds from potential tariffs, U.S. drug pricing policies, and competition from 'compounders' offering cheaper alternatives.
- Recent leadership and board changes indicate internal challenges and a need for demonstrated progress in the U.S. market.
- Future competition will likely increase from multiple drugmakers, and next-generation weight loss treatments are in development.